$SNNC interesting and huge potential imo.. Some talking on twitter and other places.
Sibannac, Inc. Files Annual Report - Early Begins Preparations to Become Fully AuditedPress Release | 10/06/2022
Scottsdale, Arizona--(Newsfile Corp. - October 6, 2022) - Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the "Company"), announced the following:
Sibannac completed and filed its annual report for Fiscal Year 2022 on September 12th, more than 75 days early. This was the result of extensive preparations to begin and complete a full audit of our books and file to become a fully reporting company. This will also streamline the process for the Company to register the warrants relating to the acquisition of the brand IP from NOHO, Inc. (OTC Pink: DRNK), which is now being finalized.
NOHO has completed the acquisition of Smog Armor, Inc. and is awaiting the processing of necessary filings which have been submitted to Wyoming to finalize that transaction. The Smog Armor team will be appointing a new slate of directors for NOHO and the company will be under completely new management, with no direct affiliation with Sibannac. It is anticipated that NOHO, Inc. will be instituting a name and ticker change consistent with the Smog Armor branding.
In addition to acquiring the NOHO After Shot, Sibannac will be moving forward with additional formulations for the NOHO brand to add to the stable of consumer goods in the wellness space. Currently the After Shot is for sale direct-to-consumer through the NOHO site, which will continue to operate seamlessly. The line extensions will be coming to market, likely in the first quarter of 2023.
Sibannac's premium wellness brand - Cherryology - now has its first completed product designed and formulated by renowned product guru, Gary Kehoe. The product is a dissolvable that targets a female demographic and is designed to induce relaxation and "Wind-Down", helping prepare the body for natural sleep. The product is now being commercialized for consumer release in 2023.
Sibannac, Inc. Selects Digital Distro, Inc./Universal Systems, Inc. for Next Generation Metaverse and NFT MarketplacePress Release | 08/10/2022
Scottsdale, Arizona--(Newsfile Corp. - August 10, 2022) - Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the "Company"), announced the following:
Sibannac's Campus Co. is proud to announce the selection of Digital Distro, Inc./ Universal Systems, Inc. to provide consulting and technology platforms for new revenue streams and distribution channels through Web3, Metaverses and NFT solutions. David Mersky, CEO, states, "We are truly excited about the technology offering from Digital Distro which brings the most advanced utility strategies within an NFT to create one-of-kind Digital Media Experiences (DMEs) specifically designed for Metaverse sales and product distribution. The expert consulting from Digital Distro with their deep understanding of Web3, NFT utility and marketplace strategies will bring the Sibannac brand and product experience to a new level. We are already seeing notable brands launch a metaverse strategy and we believe that Sibannac should have its own strategy and product offering to be at this new intersection of retail and commerce."
Mr. Mersky adds, "After we saw and experienced first-hand the level of expertise and commitment to supporting Sibannac into Web3, we knew we had the right partner to expand our vision and mission of increased revenues. Digital Distro will provide the consulting and technical expertise for Metaverse strategy/integration, NFT development, Web3 integration, NFT drops, rewarding, sharing and growing the Sibannac community."
Sibannac, Inc. and SPUR Biotech, LLC Ink Letter of Intent to Acquire the Plant Based Vaccine ManufacturerPress Release | 08/03/2022
Scottsdale, Arizona--(Newsfile Corp. - August 3, 2022) - Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the "Company"), announced the following:
The Company is proud to announce the entry into a Letter of Intent with SPUR Biotech, LLC ("SPUR"), to acquire the Ohio-based developer of plant-based vaccines. Spur is already an existing marketing client of Sibannac's Campus, its technology incubator. The Campus was created to attract clients with the aim of providing mentoring and manufacturing services and choosing a select group to pursue merger or acquisition opportunities.
SPUR is a bio-technology company developing plant-based vaccines using Controlled Environment Agriculture (CEA) to sustainably grow leafy greens and biopharmaceuticals. The vaccine under development is derived from lettuce, which is ideal for bio-reactive products. The companies previously executed an agreement wherein Sibananc, through the Campus platform, would create the market positioning for Spur's plant-based vaccines, currently in development. The Company has monitored Spur's progress, consistent with the Campus' strategy to identify new technology and design a market approach, including funding, to bring new products, like Spur's proprietary vaccine, to market.
The advantages and benefits from plant-based vaccines are that they can be grown quickly and do not require refrigeration. The administration of these vaccines is simple, as they can be taken by patients orally and do not require syringes or a professional medical visit. In addition, high protein lettuce uses the body's own bio-factory to create a natural immune response. This novel, plant-based approach utilizes quality controlled hydroponic vertical farming techniques to grow organic lettuce as the carrier. This process also provides for a low manufacturing cost and utilizes existing equipment and technology whose end-product is easy and inexpensive to transport, even across the world.
As the relationship has progressed, the parties now desire to enter into an acquisition agreement wherein Sibannac will acquire up to 46.5% ownership of Spur, with an option to purchase a majority stake in vaccine company, for additional consideration comprised of stock and cash. Since the initial marketing agreement, Spur has now advanced to the trial stage in the regulatory process. Following the advancement of the science, some of the researchers from Akron University working with Spur have now become shareholders of the firm.
SPUR BioTech is creating high performance plant bio-derived products from genetically modified plant crops as attractive alternates for biopharmaceuticals. The firm's protected IP technologies enable the biochemical tailoring of targeted molecules using a non-transgenic plant stem cell which is then genetically modified through plant crop breeding, thus yielding high thru-put propagation and rapid automated full spectrum biome crop growing. The genetic modifications are achieved in part through a DNA process called transcription.
Spur filed its final patents in June. Spur has provided Sibannac projections on the vaccine production, which reveal that millions of vaccine doses can be manufactured from lettuce grown on only two acres, demonstrating the extreme efficiency and scalability of the vaccine.
Sibannac's CEO, David Mersky, said, "The deal with SPUR is advancing beyond our initial expectations as their primary marketer. It's now clear that they have some extremely relevant tech that could add tremendous value to Sibannac's health and wellness platform. Having a marketable and approved anti-viral vaccine in our arsenal will immediately differentiate Sibannac."
Other Developments
Sibannac has also executed the deal to acquire all IP including the NOHO Aftershot from NOHO, Inc., which is pending board approvals and is expected to close within the next two weeks. The Aftershot, currently for sale direct-to-consumer through its website, has been reformulated by Gary Kehoe and his renowned formulation team out of Scottsdale, AZ. The new formula uses branded ingredients which have been clinically tested. In addition, Mr. Kehoe is in the final stages of another formulation for Sibannac, involving a relaxation product targeted to women. The product is planned to be marketed under the Company's Cherryology brand, which should be available for purchase in the Fall of 2022.
